Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 20 of 80« First...10...1819202122...304050...Last »

Sanofi says LixiLan diabetes drug trials meet targets

France’s Sanofi said two late-stage Phase III clinical trials of its LixiLan diabetes drug had met their targets, readying it for approval in the United States in August and Europe in early 2017.

Read More »

Emerging therapeutic company investment and deal trends

The Biotechnology Industry Organization released a report titled: Emerging Therapeutic Company Investment and Deal Trends. BIO Industry Analysis says more than 90 percent of the biopharma industry is composed of small, emerging companies. According to BIO President Jim Greenwood and E. Cartier Esham, Ph.D., executive VP of BIO’s Emerging Companies Section, it is important for the trade association to better understand early-stage investor and deal-making trends in order to determine where scientific or policy issues may be affecting the ability to maintain a robust pipeline of innovative medicines.

Read More »

Projected blockbuster bio products with potential launches in 2016

Dupilumab, Regeneron/Sanofi Dupilumab is the first systemic therapy to demonstrate positive Phase III results in patients with moderate-to-severe atopic dermatitis. The serious, chronic inflammatory skin disease is marked by widespread rash, itching and associated psychosocial comorbidities. Dupilumab inhibits interleukin-4 and interleukin-13, which are small anti-inflammatory proteins secreted by cells that are thought to play a […]

Read More »

Bio company stocks to watch

Here are five company stocks that some industry analysts say are under the radar and/or could be a great bargain in 2016 per sources …

Read More »

Biotech company of the year

Immunocore was recognized as SCRIP Awards 2015’s Biotech of the Year. Immunocore is a world-leading biotech company developing novel T cell receptor (TCR) based biological drugs for the treatment of cancer, viral infections and autoimmune disease.

Read More »

J&J, GSK rheumatoid arthritis drug meets study goals

An experimental drug for RA from Johnson & Johnson and GlaxoSmithKline slowed joint damage and improved symptoms of the disease, meeting the main goals of a large, late-stage trial.

Read More »

Obesity rates rising for U.S. women and teens

Obesity rates for U.S. women and teens are on the rise, according to two new studies from the U.S. Centers for Disease Control and Prevention (CDC) published in JAMA.

Read More »

Biogen’s MS drug misses main goal in study

Biogen Inc.’s keenly watched experimental drug for treating multiple sclerosis failed to meet the main goal of improving some symptoms in a mid-stage study.

Read More »

How to Vet the Best Consultants for Your Project

It’s a challenge to find and select the right consultants for a clinical study or drug trial.

Read More »

GSK seeks lead in triple lung drug market

GlaxoSmithKline is on track to file its three-in-one inhaled lung drug for U.S. approval by the end of 2016 rather than during first-half 2018 as initially planned.

Read More »

BioMarin Shutters Its Kyndrisa Duchenne Program

San Rafael, California-based BioMarin Pharmaceutical announced that it is abandoning its Kyndrisa (drisapersen) program for Duchenne muscular dystrophy (DMD).

Read More »

GSK lung drug succeeds in big UK study

GlaxoSmithKline’s new inhaled drug Breo proved significantly better than standard care in a large British study that tested it in everyday use after the failure of another big trial in 2015.

Read More »

Novartis launches new Entresto trials to boost sales

Novartis’s heart failure drug Entresto will be subjected to a battery of new trials as the Swiss drugmaker seeks to boost the medicine after a disappointing introduction.

Read More »

Oramed says oral insulin succeeds in midstage type 2 diabetes trial

Oramed Pharmaceuticals’ experimental oral insulin succeeded in significantly reducing night-time blood glucose in a midstage trial.

Read More »

Beyond immuno-oncology, AstraZeneca builds up ‘DNA damage’ drugs

Drugs targeting DNA repair mechanisms inside cells are showing real promise for a range of tumors.

Read More »

WHO recommends new test, treatment plan for superbug strains of TB

The World Health Organization has recommended a speedier, cheaper treatment plan for patients with superbug forms of TB.

Read More »

Lead Discovery Center and Boehringer Ingelheim Join Forces

Boehringer Ingelheim gains option to exclusive rights to a new lead compound for schizophrenia.

Read More »

Chimerix’s Brincidofovir Fails Another Late-Stage Study

Biopharma company Chimerix reported top-line results from an interim analysis of the AdVise trial of brincidofovir for serious adenovirus (AdV) infection.

Read More »

Second baby gets Cellectis ‘designer’ cells to clear leukemia

A second baby with aggressive leukemia has been treated in London with “designer immune cells” developed by Cellectis and, six months after treatment, she remains in remission.

Read More »

Artificial vision device may help nearly blind people

People with very poor vision may benefit from using a device that recognizes faces, money and text, a small study suggests.

Read More »

Page 20 of 80« First...10...1819202122...304050...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

December 2017 Focus: Ad Agency Roundtable and more!


Ad Right Bottom

Main Navigation